These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 37563605)
1. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis. Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605 [TBL] [Abstract][Full Text] [Related]
2. Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5. Vogiatzi F; Brandt DT; Schneikert J; Fuchs J; Grikscheit K; Wanzel M; Pavlakis E; Charles JP; Timofeev O; Nist A; Mernberger M; Kantelhardt EJ; Siebolts U; Bartel F; Jacob R; Rath A; Moll R; Grosse R; Stiewe T Proc Natl Acad Sci U S A; 2016 Dec; 113(52):E8433-E8442. PubMed ID: 27956623 [TBL] [Abstract][Full Text] [Related]
3. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Li D; Marchenko ND; Moll UM Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290 [TBL] [Abstract][Full Text] [Related]
4. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1. Tong X; Xu D; Mishra RK; Jones RD; Sun L; Schiltz GE; Liao J; Yang GY J Biol Chem; 2021; 296():100098. PubMed ID: 33208462 [TBL] [Abstract][Full Text] [Related]
5. Pancreatic Cancer Progression Relies upon Mutant p53-Induced Oncogenic Signaling Mediated by NOP14. Du Y; Liu Z; You L; Hou P; Ren X; Jiao T; Zhao W; Li Z; Shu H; Liu C; Zhao Y Cancer Res; 2017 May; 77(10):2661-2673. PubMed ID: 28280038 [TBL] [Abstract][Full Text] [Related]
6. The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells. Klemke L; Fehlau CF; Winkler N; Toboll F; Singh SK; Moll UM; Schulz-Heddergott R Front Oncol; 2021; 11():642603. PubMed ID: 34178628 [TBL] [Abstract][Full Text] [Related]
7. Proteasomal and autophagy-mediated degradation of mutp53 proteins through mitochondria-targeting aggregation-induced-emission materials. Wang M; Yang Z; Song Y; Wei P; Ishiwme N; Wang L; Zhang H; Jing M; Gao M; Wen L; Zhang Y Acta Biomater; 2022 Sep; 150():402-412. PubMed ID: 35931280 [TBL] [Abstract][Full Text] [Related]
8. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Alexandrova EM; Yallowitz AR; Li D; Xu S; Schulz R; Proia DA; Lozano G; Dobbelstein M; Moll UM Nature; 2015 Jul; 523(7560):352-6. PubMed ID: 26009011 [TBL] [Abstract][Full Text] [Related]
9. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells. Cai J; Xia J; Zou J; Wang Q; Ma Q; Sun R; Liao H; Xu L; Wang D; Guo X FEBS Open Bio; 2020 Apr; 10(4):535-545. PubMed ID: 32027103 [TBL] [Abstract][Full Text] [Related]
10. In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis. Li Y; Xiao Y; Lin HP; Reichel D; Bae Y; Lee EY; Jiang Y; Huang X; Yang C; Wang Z Biomaterials; 2019 Jan; 188():160-172. PubMed ID: 30352320 [TBL] [Abstract][Full Text] [Related]
11. Association of the thyrotropin receptor with calnexin, calreticulin and BiP. Efects on the maturation of the receptor. Siffroi-Fernandez S; Giraud A; Lanet J; Franc JL Eur J Biochem; 2002 Oct; 269(20):4930-7. PubMed ID: 12383251 [TBL] [Abstract][Full Text] [Related]
12. Calnexin, calreticulin, and ERp57 cooperate in disulfide bond formation in human CD1d heavy chain. Kang SJ; Cresswell P J Biol Chem; 2002 Nov; 277(47):44838-44. PubMed ID: 12239218 [TBL] [Abstract][Full Text] [Related]
13. Pro-metastatic p53 mutants control folding of N-glycoproteins. Schneikert J; Stiewe T Cell Cycle; 2017 Apr; 16(7):591-592. PubMed ID: 28166433 [No Abstract] [Full Text] [Related]
14. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins. Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706 [TBL] [Abstract][Full Text] [Related]
15. Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles. Zhang H; Zhang W; Hu B; Qin X; Yi T; Ye Y; Huang X; Song Y; Yang Z; Qian J; Zhang Y J Nanobiotechnology; 2023 Apr; 21(1):117. PubMed ID: 37005668 [TBL] [Abstract][Full Text] [Related]
16. BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function. Yue X; Zhao Y; Liu J; Zhang C; Yu H; Wang J; Zheng T; Liu L; Li J; Feng Z; Hu W Elife; 2015 Aug; 4():. PubMed ID: 26271008 [TBL] [Abstract][Full Text] [Related]
17. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy. Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900 [TBL] [Abstract][Full Text] [Related]
18. Contrasting functions of calreticulin and calnexin in glycoprotein folding and ER quality control. Molinari M; Eriksson KK; Calanca V; Galli C; Cresswell P; Michalak M; Helenius A Mol Cell; 2004 Jan; 13(1):125-35. PubMed ID: 14731400 [TBL] [Abstract][Full Text] [Related]
19. Steroid receptor coactivator-1 upregulates integrin α₅ expression to promote breast cancer cell adhesion and migration. Qin L; Chen X; Wu Y; Feng Z; He T; Wang L; Liao L; Xu J Cancer Res; 2011 Mar; 71(5):1742-51. PubMed ID: 21343398 [TBL] [Abstract][Full Text] [Related]
20. In vitro assays of the functions of calnexin and calreticulin, lectin chaperones of the endoplasmic reticulum. Ireland BS; Niggemann M; Williams DB Methods Mol Biol; 2006; 347():331-42. PubMed ID: 17072021 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]